Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion’s Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex for the past 12 months were approximately $474 million.
Read the Watson press release.
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
